Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label randomized trial of SMT19969 vs fidaxomicin for Clostridium difficile infection
2013-005483-25Phase 2Completed
- Sponsor
- Summit Therapeutics
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ridinilazole in Clostridioides difficile colitis (CDI) (2 arms), sponsored by Summit Therapeutics. Primary endpoint: Number of adverse events and serious adverse events. Started Jul 2014; status: completed.
02
Drugs
ridinilazole
03
Conditions
Clostridioides difficile colitis (CDI)
Beyond the preview
Go deeper on 2013-005483-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005483-25.